

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 June 2005 (09.06.2005)

PCT

(10) International Publication Number
WO 2005/051395 A1

(51) International Patent Classification⁷: **A61K 31/5375**,
A61P 25/22

Science Park South, Third Avenue, Harlow Essex CM19
5AW (GB).

(21) International Application Number:
PCT/EP2004/013499

(74) Agent: **REED, Michael**; GlaxoSmithKline, C.I.P.
(CN925.1), 980 Great West Road, Brentford Middlesex
TW8 9GS (GB).

(22) International Filing Date:
25 November 2004 (25.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0327619.3 27 November 2003 (27.11.2003) GB

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, P.O. Box 7929, Philadel-
phia, Pennsylvania 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DEELY, Ju-
dith, Bramel** [US/US]; GlaxoSmithKline, Five Moore
Drive, Research Triangle Park, Durham, North Car-
olina 27709 (US). **GERRARD, Philip, Alan** [GB/IT];
GlaxoSmithKline S.p.A., Via Alessandro Fleming, 2,
I-37135 Verona (IT). **GOODALE, Elizabeth, Parsons**
[US/US]; GlaxoSmithKline, Five Moore Drive, Research
Triangle Park, Durham, North Carolina 27709 (US).
LEARNED-COUGHILIN, Susan, Marie [US/US];
GlaxoSmithKline, Five Moore Drive, Research Triangle
Park, Durham, North Carolina 27709 (US). **NOBBS, Mal-
colm, Stuart** [GB/GB]; GlaxoSmithKline, New Frontiers

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: (+) - (2S, 3S) -2- (3-CHLOROPHENYL) -3, 5, 5-TRIMETHYL-2-MORPHOLINOR FOR TREATING ANXIETY

(57) Abstract: This invention relates to a novel use of (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol hydrochloride or a salt or solvate thereof, in particular its use in the treatment of anxiety disorders or in the treatment of mixed anxiety-depressive disorder.

WO 2005/051395 A1